ライフサイエンスコーパス: nucleoside analog

1 pegylated interferon and ribavirin (RBV), a nucleoside analog.

2 .5 determined for tenofovir, another acyclic nucleoside analog.

3 py can enhance the efficacy of an anticancer nucleoside analog.

4 sted even after prolonged treatment with the nucleoside analog.

5 explain the biological consequences of this nucleoside analog.

6 ns to circumvent the antiviral resistance of nucleoside analogs.

7 side effects commonly seen with conventional nucleoside analogs.

8 mes with new and improved activities towards nucleoside analogs.

9 ons and will suggest future plans with these nucleoside analogs.

10 similar to that reported previously for the nucleoside analogs.

11 the active metabolite for both these purine nucleoside analogs.

12 s of L-configuration but not D-configuration nucleoside analogs.

13 emic and intracellular levels of anti-cancer nucleoside analogs.

14 tructurally diverse anticancer and antiviral nucleoside analogs.

15 mal residual disease and in combination with nucleoside analogs.

16 these cells to drug-induced apoptosis using nucleoside analogs.

17 of how mutations in RT confer resistance to nucleoside analogs.

18 s could explain the enhanced excision of the nucleoside analogs.

19 the misincorporation and excision of several nucleoside analogs.

20 so alter the therapeutic efficacy of certain nucleoside analogs.

21 specific enzyme, thymidine kinase (TK), with nucleoside analogs.

22 se can preferentially excise l-configuration nucleoside analogs.

23 ncer cells, including the lines resistant to nucleoside analogs.

24 ntly rests with long-term therapy using oral nucleoside analogs.

25 Two pyrimidine nucleoside analogs, [18F]FEAU (1-(2'-deoxy-2'-fluoro-bet

26 The antiretroviral nucleoside analog 2',3'-dideoxy-3'-thiacytidine (3TC) is

27 The nucleoside analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-p

28 ucleoside kinase pathway activity, we used a nucleoside analog 2'3'-dideoxycytidine (ddC), which is p

29 The nucleoside analog 2-chloro-2'-deoxyadenosine (CldAdo; cl

30 The archetypical fluorescent nucleoside analog, 2-aminopurine (2Ap), has been used in

31 The pteridine nucleoside analog 3-methyl isoxanthopterin (3-MI) is hig

32 However, the sensitivity of HIV-1 to the nucleoside analog 3TC was not affected by the level of R

33 In contrast, a nucleoside analog (3TC-TP, triphosphate form of lamivudi

34 The nucleoside analog 5-aza-2'-deoxycytidine (5-aza-CdR, dec

35 75 melanoma cells with the DNA demethylating nucleoside analog 5-AZA-2'-deoxycytidine (5-AZA-dC) syne

36 The nucleoside analog 5-azacytidine is an archetypical drug

37 D relies on labeling of nascent DNA with the nucleoside analog 5-ethynyl-2'-deoxyuridine (EdU).

38 ditions in which transport of the pyrimidine nucleoside analog 5-fluorodeoxyuridine (FUdR) would inhi

39 porter Fui1 confers sensitivity to the toxic nucleoside analog 5-fluorouridine.

40 phenotype was confirmed using two additional nucleoside analogs, 5-azacytidine and ribavirin.

41 We introduced the nucleoside analog 8-azanebularine (8-azaN) into this RNA

42 tiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, provid

43 ) resistance can involve the excision of the nucleoside analog after it has been incorporated into vi

44 reby playing a key role in the activity of l-nucleoside analogs against human immunodeficiency virus,

45 tics have also stimulated efforts to develop nucleoside analogs against other positive-strand RNA vir

46 on the safety of long-term therapy with the nucleoside analogs, alone and in combination, are needed

47 delayed chain termination may complement the nucleoside analogs already approved for HIV-1 therapy.

48 was investigated using a series of unnatural nucleoside analogs and a representative PAH diolepoxide,

49 other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in co

50 ure of the E. coli enzyme in complex with 10 nucleoside analogs and correlated the structures with ki

51 se that is less important for the binding of nucleoside analogs and deoxynucleoside triphosphates.

52 by combining different drug classes such as nucleoside analogs and HIV protease inhibitors (PIs), ha

53 1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors.

54 1 protein in cellular response to anticancer nucleoside analogs and precursors, which act without des

55 ents for this patient group, including novel nucleoside analogs and several other agents.

56 gy to increase the antitumor activity of the nucleoside analogs and to overcome tumor cell resistance

57 en treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS

58 creased the sensitivity of HIV-1 to multiple nucleoside analogs, and a subset of these Q151 variants

59 n of a quasispecies, the choice of mutagenic nucleoside analogs, and the studies that have demonstrat

60 how that patients treated with commonly used nucleoside analog anti-retroviral drugs progressively ac

61 l-Nucleoside analogs are a new class of clinically active

62 These nucleoside analogs are called "delayed chain terminators

63 Several new nucleoside analogs are currently in development for the

64 Several nucleoside analogs are effective in treating leukemias a

65 Many new nucleoside analogs are emerging with novel metabolic pro

66 Nucleoside analogs are frequently used to label newly sy

67 Nucleoside analogs are important in the treatment of hem

68 ar determinants of specificity for synthetic nucleoside analogs are not known.

69 Anticancer and antiviral D- and L-nucleoside analogs are phosphorylated stepwise in the ce

70 Nucleoside analogs are structurally similar antimetaboli

71 Nucleoside analogs are structurally, metabolically, and

72 e mutations that cause resistance to several nucleoside analogs are the insertion of amino acids in t

73 the natural configuration, as well as the L-nucleoside analogs, are clinically relevant antiviral an

74 some of these goals are being met, and that nucleoside analogs as a class of compounds remain fertil

75 Here, we used genetic and nucleoside analog-based tools to mark and track the orig

76 give slightly improved affinities: bicyclic nucleoside analogs (BCNAs) with a p-alkyl-substituted ph

77 sis, stability and polymerase recognition of nucleoside analogs bearing single bromo- or cyano-deriva

78 es that are activated by clinically relevant nucleoside analogs begins to provide a mechanistic basis

79 lar K(m) value for matched, 3' mispaired, or nucleoside analog beta-l-dioxolane-cytidine terminated n

80 es on HIV reverse transcriptase suggest that nucleoside analogs bind more tightly to the enzyme than

81 apy or in combination with cyclophosphamide, nucleoside analog, bortezomib, or thalidomide-based regi

82 eads to a reduced ability to incorporate the nucleoside analog BrdU, indicating that ASF1 is required

83 immunodeficiency virus (SIV) infection, the nucleoside analog bromodeoxyuridine (BrdU) was administe

84 rmation of the triphosphate metabolites of l-nucleoside analogs (but not d-nucleoside analogs), resul

85 HIV-1 can become resistant to nucleoside analogs by developing an enhanced ability to

86 In contrast, the cytostatic activity of nucleoside analogs carrying a highly toxic purine base a

87 Flow cytometry analyses validate that the nucleoside analog causes apoptosis by blocking cell cycl

88 Clinically, this moderately toxic nucleoside analog causes peripheral neuropathy, hematolo

89 stem cells in the synovium in vivo, a double nucleoside analog cell-labeling scheme was used in a mou

90 that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) re

91 Although the nucleoside analogs cladribine and pentostatin produce hi

92 We conducted a phase 1 study of a novel nucleoside analog, clofarabine, in pediatric patients wi

93 We assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II

94 also cross-resistant to cytarabine, another nucleoside analog commonly used in cancer therapy, and 4

95 ding, we developed a "push-pull" fluorescent nucleoside analog composed of dimethylaniline (DMA) fuse

96 e the molecular basis for the development of nucleoside analog compounds with selective activity agai

97 y double and triple immunostaining to detect nucleoside analogs, conventional MSC markers, and chondr

98 Thus it was postulated that these nucleoside analogs could exert their antiviral effect vi

99 Chain-terminating nucleoside analogs (CTNAs) that cause stalling or premat

100 8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the t

101 e natural nucleotides and the five antiviral nucleoside analogs currently approved for antiviral ther

102 The nucleoside analog cytarabine (Ara-C) is an essential com

103 lated that SAMHD1 sensitizes cancer cells to nucleoside-analog derivatives through the depletion of c

104 phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of

105 Of potential interest for nucleoside analog development, T. brucei TK was less dis

106 nt antiretroviral treatment consisted of the nucleoside analog didanosine in the first 43 patients en

107 study also suggests the potential impact of nucleoside analog diphosphates and triphosphates on the

108 ty of the phosphorylating enzymes toward the nucleoside analog diphosphates is dependent on the confi

109 matic process of phosphorylation of L- and D-nucleoside analog diphosphates is different in cells.

110 Metabolism of L-nucleoside analog diphosphates to the triphosphates, how

111 nt nm23-H1 and -H2 isoforms indicated that L-nucleoside analog diphosphates were not phosphorylated b

112 preparations from HepG2 cells showed that L-nucleoside analog diphosphates were selectively phosphor

113 le for the phosphorylation of all classes of nucleoside analog diphosphates.

114 ed distinction in the metabolism of l- and d-nucleoside analogs, disputing the classic notion that nu

115 fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-beta-D-ribofuranos

116 and rCNT2) in their ability to transport the nucleoside analog drug cladribine, 2CdA, (rCNT2 > > > hC

117 port of naturally-occurring nucleosides, and nucleoside analog drugs across the plasma membrane of ep

118 max and K0.5 for substrate at -50 mV for the nucleoside analog drugs gemcitabine (638+/-58 nA, 59.7+/

119 ating hepatitis B virus (HBV) infection with nucleoside analog drugs like lamivudine is limited by th

120 Nucleoside analog drugs that target viral DNA replicatio

121 transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and pr

122 ter its ability to transport nucleosides and nucleoside analog drugs.

123 the ability of many organisms to incorporate nucleoside analogs during DNA replication, together with

124 een few prospective studies on the safety of nucleoside analogs during pregnancy.

125 the chemoresistance of pancreatic cancer to nucleoside analogs (e.g., gemcitabine).

126 To investigate this, we introduced nucleoside analogs either individually or in tandem into

127 ed and viral DNA levels were quantified from nucleoside analog-experienced children prior to and duri

128 a randomized study of 3 therapy regimens in nucleoside analog-experienced patients.

129 ome inhibitors (bortezomib and carfilzomib), nucleoside analogs (fludarabine and cladribine), and ibr

130 dying the incorporation of alkyne-conjugated nucleoside analogs followed by a fluorescent azide-coupl

131 oteins as well as new progress in the use of nucleoside analogs for inducing lethal mutagenesis have

132 ative and unified structural requirements of nucleoside analogs for interaction with hCNT1, hCNT2, an

133 els in the form of conjugates with activated nucleoside analogs for oral administration in cancer che

134 lications of this work on the development of nucleoside analogs for treatment of HCV infection.

135 exible preparation of three classes of these nucleoside analogs from common precursors-properly subst

136 Furthermore, as the nucleoside analog ganciclovir is the current drug of cho

137 The anticancer nucleoside analog gemcitabine had a reduced affinity for

138 roRNA-21 to be a driver of resistance to the nucleoside analog gemcitabine in human adenocarcinoma ce

139 All nucleoside analogs have a "Black Box" warning because of

140 Long-term therapy with nucleoside analogs, however, raises a number of practica

141 ectively interfere with the incorporation of nucleoside analogs; however, it has only recently been p

142 Targeted screening of nucleoside analogs identified R1479 (4'-azidocytidine) a

143 s and typically conferred resistance to both nucleoside analogs in cell culture.

144 cond, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformatio

145 m of resistance in response to abacavir, and nucleoside analogs in general, a set of reverse transcri

146 We tested a class of nucleoside analogs in which a pseudosugar ring is locked

147 rom Thermus thermophilus HB8 and a series of nucleoside analogs in which the mechanism of discriminat

148 8-Aminoadenosine (8-NH(2)-Ado), a ribosyl nucleoside analog, in preclinical models of multiple mye

149 ere not altered in their susceptibilities to nucleoside analogs; in fact, some of the mutants were hy

150 tential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a

151 a variety of pyrimidine and acycloguanosine nucleoside analogs, including clinically used antiviral

152 at signify various stages of the cell cycle: nucleoside-analog incorporation, cell cycle-associated p

153 osure to nucleotide analogues, compared with nucleoside analogs, increased the risk of hip fracture (

154 Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HC

155 y asking if treatment of woodchucks with the nucleoside analog inhibitor of viral DNA synthesis entec

156 ves of Lys154 were completely resistant to a nucleoside analog inhibitor, 3'-dideoxy 3'-thiacytidine

157 very, from microbial-extract screening, of a nucleoside-analog inhibitor that inhibits bacterial RNA

158 ants exhibited altered susceptibility to the nucleoside analog inhibitors AZT and 3TC.

159 to influence its fidelity and sensitivity to nucleoside analog inhibitors.

160 PPT substrates substituted with a variety of nucleoside analogs [inosine (I), purine riboside (PR), 2

161 In the present study we have used nucleoside analog interference mapping to probe A3G-DNA

162 We have combined nucleoside analog interference with chemical footprintin

163 e long-chain fatty acid amide derivatives of nucleoside analogs into solid lipid nanoparticles may re

164 it is evident that the toxicity of antiviral nucleoside analogs is determined in part by the extent t

165 However, prolonged treatment with nucleoside analogs is often needed to optimize virologic

166 An important mechanism of resistance to nucleoside analogs is the enhanced excision of the analo

167 Acyclovir, a nucleoside analog, is thought to be specific for the hum

168 ions associated with resistance to antiviral nucleoside analogs (K65R, L74V, E89G, Q151N, and M184I)

169 fore and during 30 weeks of therapy with the nucleoside analog L-FMAU [1-(2-fluoro-5-methyl-beta, L-a

170 inofuranoside (Ara-C) treatment and a double nucleoside analog-labeling technique.

171 2M confers marked hypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir at bot

172 the oxathiolane ring (common to both beta-L-nucleoside analogs lamivudine and emtricitabine) is prop

173 The toxicity of nucleoside analogs may be related to their effects on th

174 Combinations of nucleoside analogs may offer an approach to preventing a

175 at potentially may have an important role in nucleoside analog metabolism.

176 activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and

177 h two oxidative traps, a site containing the nucleoside analog methylindole (5'-GMG-3') and a 5'-GGG-

178 Treatment of cells with other nucleoside analogs modified at C-5, 5-fluorodeoxyuridine

179 to measure tumor determinants of response to nucleoside analog (NA) chemotherapy agents such as gemci

180 e often the rate-limiting step in activating nucleoside analog (NA) prodrugs into their cytotoxic, ph

181 Nucleoside analogs (NAs) are considered as appropriate a

182 Nucleoside analogs (NAs) represent an important category

183 ave been approved to treat HIV-1 infections, nucleoside analogs (NRTIs) and nonnucleosides (NNRTIs),

184 se transcriptase (RT): the chain-terminating nucleoside analogs (NRTIs) and the allosteric nonnucleos

185 ylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator ag

186 propyl)adenine (DHPA), a plausibly prebiotic nucleoside analog of adenosine.

187 e methylation machinery in tumor cells using nucleoside analogs of cytosine, such as 5-aza-2'-deoxycy

188 type 1 (HIV-1) reverse transcriptase (RT) to nucleoside analogs: one in which the mutations interfere

189 preclinical and clinical findings with other nucleoside analogs or normal deoxynucleotides such as dG

190 y recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy.

191 ncorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or

192 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed

193 imab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination

194 Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C vi

195 Several nucleoside analog prodrugs are dependent on dCK for thei

196 dCK phosphorylates and therefore activates nucleoside analog prodrugs frequently used in cancer, au

197 e activation cascade of medicinally relevant nucleoside analog prodrugs such as AraC, gemcitabine, an

198 acetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling

199 Several cytostatic purine nucleoside analogs proved to be susceptible to PNPHyor-m

200 Fluorescent nucleoside analogs provide a means to study DNA interact

201 of the structural basis for activation of L-nucleoside analogs, providing further impetus for discov

202 While the nucleoside analog RBV improves treatment outcome, and wi

203 ith relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly f

204 Nucleoside analogs remain a cornerstone in acute myeloid

205 L-nucleoside analogs represent an important class of small

206 tabolites of l-nucleoside analogs (but not d-nucleoside analogs), resulting in detrimental effects on

207 virus (FV) replication is resistant to most nucleoside analog reverse transcriptase (RT) inhibitors.

208 azanavir-ritonavir at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTI

209 Nucleoside analog reverse transcriptase inhibitors (NRTI

210 ing resistance to protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors, and

211 rapy is limited to an off-labeled use of the nucleoside analog ribavirin, which has limited prophylac

212 nt virus was more resistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the

213 strategy against influenza virus using three nucleoside analogs, ribavirin, 5-azacytidine, and 5-fluo

214 ining tenofovir disoproxil fumarate or other nucleoside analog RT drugs.

215 We found that the replication of nucleoside analog RT inhibitor-, nonnucleoside analog RT

216 was observed between the aptamer and the two nucleoside analog RT inhibitors (azidothymidine triphosp

217 criptase (RT) is selected in vitro by many D-nucleoside analog RT inhibitors (NRTI) but has been rare

218 dine triphosphate or ddCTP), whereas two non-nucleoside analog RT inhibitors showed either weak syner

219 We have shown that the phosphonated nucleoside analog, (S)-1-[3-hydroxy-2-(phosphonylmethoxy

220 Thus, fission yeast responds to nucleoside analogs similarly to mammalian cells, which h

221 T-containing RNA/DNA hybrid are sensitive to nucleoside analog substitution, whereas the intervening

222 f action quite distinct from that of acyclic nucleoside analogs such as acyclovir (ACV) that is based

223 plex virus is a major pathogen, and although nucleoside analogs such as acyclovir are highly effectiv

224 These include D-nucleoside analogs such as beta-D-2',3'-dideoxycytidine

225 ro-2',3'-dideoxythymidine (D4T) as well as L-nucleoside analogs such as beta-L-dioxolane-cytidine (L-

226 nusual protein kinase that can phosphorylate nucleoside analogs such as ganciclovir but whose specifi

227 late certain exogenous substrates, including nucleoside analogs such as ganciclovir.

228 late certain exogenous substrates, including nucleoside analogs such as ganciclovir.

229 Nucleoside analogs such as gemcitabine diphosphate and c

230 fication is based on their ability to retain nucleoside analog, such as bromodeoxyuridine.

231 therapies for herpes viral infections employ nucleoside analogs, such as Acyclovir, and target the vi

232 Monotherapy with nucleoside analogs, such as lamivudine and famciclovir,

233 Newer more potent nucleoside analogs (tenofovir and entecavir) have proven

234 asia (t-MDS) occurs less frequently with the nucleoside analogs than with DNA-damaging agents such as

235 ldAdo thus represents the first example of a nucleoside analog that acts as a transcriptional antagon

236 FLT is a nucleoside analog that enters cells and is phosphorylate

237 infectivity can be decreased by combining a nucleoside analog that forms noncanonical base pairs wit

238 d favorably with fludarabine, another purine nucleoside analog that is more commonly used in the trea

239 xymethylbutyl)guanine (FHBG) is an antiviral nucleoside analog that is rapidly phosphorylated by vira

240 5-Azacytidine (AZA) is a nucleoside analog that is used to treat preleukemic and

241 The antiviral drug acyclovir is a guanosine nucleoside analog that potently inhibits herpes simplex

242 ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), a nucleoside analog that retains a 3'-hydroxyl moiety, inh

243 4 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a

244 not suitable for development as drugs, other nucleoside analogs that cause delayed chain termination

245 We have describe nucleoside analogs that do not block DNA synthesis at th

246 We have developed nucleoside analogs that do not block DNA synthesis at th

247 dentify a promising strategy to design novel nucleoside analogs that exert profound antiviral activit

248 Achieving a similar phenotype with nucleoside analogs that have different effects on duplex

249 d therapeutics are largely based on modified nucleoside analogs that inhibit viral DNA polymerase fun

250 ted in the complementation assay to identify nucleoside analogs that mimic this base-mispairing and p

251 Many antiviral and anticancer drugs are nucleoside analogs that target polymerases and cause DNA

252 ngers insertion and T215Y excised all of the nucleoside analogs that were tested more efficiently tha

253 complicated by the dual activity of several nucleoside analogs, the more rapid development of lamivu

254 x, histone deacetylase inhibitors, and novel nucleoside analog therapies, have demonstrated promising

255 ic activity and resistance to treatment with nucleoside analog therapies.

256 tegies to improve on the initial response to nucleoside analog therapy are likely to be beneficial, a

257 as been shown to be effective, and long-term nucleoside analog therapy has been demonstrated to maint

258 Although antiviral nucleoside analog therapy successfully delays progressio

259 monotherapy) to 12.4% during 1997-1999 (dual-nucleoside analog therapy) and 14.3% during 2005-2009 (r

260 r a finite course of pegylated interferon or nucleoside analog therapy, with possible long-term maint

261 e more activated, which can be normalized by nucleoside analog therapy.

262 of conventional alfa interferon to a year of nucleoside analog therapy.

263 s B immunoglobulin and treatment with potent nucleoside analogs, there has been a resurgence of LT fo

264 trated effectiveness in sensitizing cells to nucleoside analogs, thus offering a means to elude drug

265 or parasite and LRV1 inhibition, focusing on nucleoside analogs to capitalize on the highly active sa

266 We have examined other nucleoside analogs to determine whether these compounds

267 hat the enzyme can selectively phosphorylate nucleoside analogs to produce products toxic to the cell

268 of reducing N-hydroxylated base analogs and nucleoside analogs to the corresponding canonical nucleo

269 lidated in the clinic, the prospect of using nucleoside analogs to treat acute infections caused by R

270 ances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA production in HBV

271 previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino

272 Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino

273 y thereafter, the introduction of the purine nucleoside analogs transformed this disease into a highl

274 to their DNA synthesis-directed actions many nucleoside analogs trigger apoptosis by unique mechanism

275 specificity constant (k(cat)/K(m)) for each nucleoside analog triphosphate.

276 o almost all drugs, including gemcitabine, a nucleoside analog used as a first-line treatment.

277 ide (cytarabine, ara-C) represent a class of nucleoside analogs used in cancer chemotherapy.

278 take of natural nucleosides and a variety of nucleoside analogs used in the chemotherapy of cancer an

279 Several of the nucleoside analogs used in the treatment of AIDS exhibit

280 ol gamma) in clinically observed toxicity of nucleoside analogs used to treat AIDS, we examined the k

281 the safety profile of the five approved oral nucleoside analogs used to treat chronic hepatitis B vir

282 n wild-type enzyme and a mutant resistant to nucleoside analogs used to treat HIV infections reveal t

283 ondria related to aging and as compounded by nucleoside analogs used to treat human immunodeficiency

284 a glycolytic enzyme, in the metabolism of l-nucleoside analogs, using small interfering RNAs to down

285 Recent experiments with mutagenic nucleoside analogs validate this new approach to treatin

286 30,000 compounds screened, a novel cytidine nucleoside analog was identified that displayed selectiv

287 he uptake and disposition of clinically used nucleoside analogs, we determined the haplotype structur

288 Regimens that included rituximab and a nucleoside analog were associated with superior rates of

289 e of 5-azacytidine's general toxicity, other nucleoside analogs were favored as therapeutics.

290 The desired 5'-O-DMT-protected nucleoside analogs were synthesized from suitably protec

291 D-Nucleoside analogs, which are in the natural configurati

292 Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that

293 binofuranosyladenine) is a second-generation nucleoside analog with activity in acute leukemias.

294 Entecavir is a nucleoside analog with potent antiviral efficacy, and in

295 s compound, 6-ethylthioinosine (6-ETI), is a nucleoside analog with toxicity to PEL in vitro and in v

296 Troxacitabine is a non-natural nucleoside analog with unique structural and metabolic f

297 This suggested that the interactions of the nucleoside analogs with amino acids during the transitio

298 s, we identified chimeras that phosphorylate nucleoside analogs with higher activity than either pare

299 nalysis of the inward currents induced by 27 nucleoside analogs with substitutions at both the ribose

300 xcision pathway to develop resistance to the nucleoside analog zidovudine (AZT), HIV-2 RT does not ap